Dyslipidemia | Unmet Need | US/EU | 2016
The most common problems associated with treating dyslipidemia are identifying patients who need to be treated, determining how aggressively they should be treated, and then encouraging them to comply with prescribed therapy. In addition, the degree of cardioprotection afforded by current agents is often suboptimal. Decision Resources Group’s Unmet Needs in Dyslipidemia analysis provides quantitative insight into U.S. and European physician perceptions of the unmet needs associated with dyslipidemia treatment, the goals of treatment, and the key drivers of therapy uptake. We discuss the commercial opportunities and how emerging therapies can capitalize on these opportunities.
Related Market Assessment Reports
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
